AllSci News
Ceruvia funds Phase I/II trial of non-hallucinogenic LSD analog for cluster headache
Greenwich, Connecticut-based Ceruvia Lifesciences announced a USD 8 million founder-backed investment to fully fund an integrated Phase I/II clinical study...
Obsidian completes Galera reverse merger and USD 350m PIPE raise
Cambridge, Massachusetts-based Obsidian Therapeutics (Nasdaq: OBX) completed its reverse merger with Galera Therapeutics on August 3, 2026, simultaneously...
Eisbach Bio patent application outlines allosteric ALC1 strategy for PARP combinations
Germany-based Eisbach Bio GmbH has published a US patent application (US20260216344A1) covering allosteric small molecule inhibitors of ALC1 (CHD1L;...
CellOrigin advances in vivo mRNA CAR-T for HCC with Walvax partnership
China-based CellOrigin Biotech (Hangzhou) Co., Ltd. has entered a co-development agreement with Walvax Biotechnology Co., Ltd. (Shenzhen: 300142) to jointly...
Aravax secures FDA Fast Track designation for PVX108 peanut allergy immunotherapy
Aravax, a clinical-stage biotechnology company headquartered in Melbourne, Australia and Oxford, UK, announced receipt of US FDA Fast Track Designation for...
Moleculin raises USD 9.3m to fund Annamycin's pivotal AML trial through interim readout
Houston-based Moleculin Biotech, Inc. (Nasdaq: MBRX) announced the pricing of a USD 9.3 million best-efforts public offering on July 31, 2026, with proceeds...
Nippon Shinyaku exercises USD 30 million option for AB2 Bio's rare disease biologic
Japan-based Nippon Shinyaku Co., Ltd. (TSE: 4516) has exercised its option to acquire exclusive US commercialization rights to tadekinig alfa,...
Supernus, Indivior agree all-stock merger to create diversified CNS biopharma
Rockville, Maryland-based Supernus Pharmaceuticals (Nasdaq: SUPN) and Richmond, Virginia-based Indivior Pharmaceuticals (Nasdaq: INDV) have agreed to merge...
Lilly's olomorasib earns FDA Breakthrough Therapy designation for KRAS G12C pancreatic cancer
Eli Lilly and Company (NYSE: LLY) announced on August 3, 2026 that the US FDA has granted Breakthrough Therapy Designation (BTD) to olomorasib (LY3537982),...
Curium to acquire Lantheus for USD 8b to build global radiopharmaceutical powerhouse
Curium, the Boston-headquartered global radiopharmaceutical company controlled by private equity firm CapVest Partners LLP, has agreed to acquire Lantheus...
China's Ractigen raises USD 31m to expand saRNA pipeline
China-based Ractigen Therapeutics has closed a financing round exceeding USD 31 million (CNY 200 million) to advance its clinical-stage small activating RNA...
China clears Insilico's BBB-penetrant NLRP3 inhibitor for Parkinson's Phase I study
Insilico Medicine (HKEX: 03696) announced on August 3, 2026 that ISM8969/HT-001, an orally available, blood-brain barrier (BBB)-penetrant NLRP3 inhibitor...
Nabsys expands electronic genome mapping into AML and MDS through Indiana University partnership
Providence, Rhode Island-based Nabsys 2.0, LLC announced a multi-year research collaboration with the Indiana University School of Medicine to evaluate its...
Ratio Therapeutics raises USD 70m Series C with Eli Lilly as new strategic investor
Boston-based Ratio Therapeutics, Inc., a clinical-stage radiopharmaceutical company, has closed a USD 70 million Series C financing round, bringing total...
Annexon secures USD 200m credit facility as late-stage programs approach market approvals
Brisbane, California-based Annexon, Inc. (Nasdaq: ANNX) announced a senior secured credit facility of up to USD 200 million from Oxford Finance LLC,...
The AllSci Brief
Free, systematic R&D and deal news. Daily.